<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2014.3286</article-id>
<article-id pub-id-type="publisher-id">or-32-03-1108</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Effect of DJ-1 overexpression on the proliferation, apoptosis, invasion and migration of laryngeal squamous cell carcinoma SNU-46 cells through PI3K/AKT/mTOR</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>BIN</given-names></name><xref rid="af1-or-32-03-1108" ref-type="aff">1</xref><xref rid="fn1-or-32-03-1108" ref-type="author-notes">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>QIN</surname><given-names>HAO</given-names></name><xref rid="af2-or-32-03-1108" ref-type="aff">2</xref><xref rid="fn1-or-32-03-1108" ref-type="author-notes">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>YUEJIAN</given-names></name><xref rid="af2-or-32-03-1108" ref-type="aff">2</xref><xref rid="fn1-or-32-03-1108" ref-type="author-notes">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHEN</surname><given-names>WEIXIONG</given-names></name><xref rid="af2-or-32-03-1108" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>LUO</surname><given-names>JIE</given-names></name><xref rid="af1-or-32-03-1108" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHU</surname><given-names>XIAOLIN</given-names></name><xref rid="af1-or-32-03-1108" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>WEN</surname><given-names>WEIPING</given-names></name><xref rid="af1-or-32-03-1108" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-or-32-03-1108"/></contrib>
<contrib contrib-type="author">
<name><surname>LEI</surname><given-names>WENBIN</given-names></name><xref rid="af1-or-32-03-1108" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-or-32-03-1108"/></contrib></contrib-group>
<aff id="af1-or-32-03-1108">
<label>1</label>Otorhinolaryngology Hospital, Otorhinolaryngology Institute, The First Affiliated Hospital, Sun Yat-sen University, National Key Department of Otorhinolaryngology of People&#x02019;s Republic of China, Guangzhou, Guangdong 510080, P.R. China</aff>
<aff id="af2-or-32-03-1108">
<label>2</label>Department of Otolaryngology, The First People&#x02019;s Hospital of Foshan, Foshan, Guangdong 528000, P.R. China</aff>
<author-notes>
<corresp id="c1-or-32-03-1108">Correspondence to: Dr Wenbin Lei or Dr Weiping Wen, Otorhinolaryngology Hospital, Otorhinolaryngology Institute, The First Affiliated Hospital, Sun Yat-sen University, National Key Department of Otorhinolaryngology of People&#x02019;s Republic of China, 58 Zhongshan 2nd Road, Guangzhou, Guangdong 510080, P.R. China, E-mail: <email>leiwb@mail.sysu.edu.cn</email>, E-mail: <email>wenwp@mail.sysu.edu.cn</email></corresp><fn id="fn1-or-32-03-1108">
<label>*</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>9</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>06</month>
<year>2014</year></pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>1108</fpage>
<lpage>1116</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>02</month>
<year>2014</year></date>
<date date-type="accepted">
<day>20</day>
<month>05</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>The aim of the present study was to explore the effect of DJ-1-mediated PI3K/AKT/mTOR pathway on the proliferation, apoptosis, invasion, migration and other tumor biological characteristics of laryngeal squamous cell SNU-46, through stable transfection and overexpression of the DJ-1 gene. Retrovirus carrying DJ-1 gene was used to stabilize transfected human laryngeal squamous carcinoma SNU-46 cell line, and monoclonal cell line of stably overexpressed DJ-1 protein was screened out by G418. DJ-1 protein expression was determined by western blotting, and changes of p-AKT, p-mTOR and PTEN protein content were detected, followed by the detection of changes in proliferation, apoptosis, invasion, migration and other tumor biological characteristics of laryngeal squamous carcinoma cell line with stably transfected DJ-1 protein overexpression by flow cytometry, CCK-8 method and Transwell. We successfully constructed a laryngeal squamous carcinoma cell line of stably overexpressed DJ-1 protein and termed it SNU-46-DJ-1. After overexpression of DJ-1 protein, the levels of PTEN expression in laryngeal squamous cell SNU-46 decreased and p-AKT and p-mTOR protein expression levels increased. Compared to the untreated SNU-46 cells, the proliferation rate of SNU-46-DJ-1 cells increased (0.834&#x000B1;0.336 vs. 0.676&#x000B1;0.112; p&lt;0.001); invasiveness was enhanced (165.7&#x000B1;13.6 vs. 100.0&#x000B1;17.4; p=0.001), the migration ability was enhanced (207.3&#x000B1;13.1 vs. 175.3&#x000B1;13.3; p=0.036), and the apoptosis rate decreased (3.533&#x000B1;5.167 vs. 16.397&#x000B1;5.447&#x00025;; p=0.019). The overexpression of DJ-1 protein in laryngeal squamous carcinoma SNU-46 cells can accelerate proliferation rate, increase the invasion and migration capacity, and reduce apoptosis, by activating the PI3K/AKT/mTOR pathway.</p></abstract>
<kwd-group>
<kwd>stable transfection</kwd>
<kwd>DJ-1</kwd>
<kwd>PTEN</kwd>
<kwd>PI3K/AKT/mTOR signaling pathway</kwd>
<kwd>SNU-46 cell line</kwd>
<kwd>laryngeal squamous carcinoma</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>DJ-1 protein was discovered in 1997 by Nagakubo <italic>et al</italic>; it is widely expressed in various human tissues, with high expression levels in testis, kidney, pancreas, heart and skeletal muscle (<xref rid="b1-or-32-03-1108" ref-type="bibr">1</xref>). The total length of the human DJ-1 gene is 24 ku, including 8 exons of which the first two do not encode proteins. The mRNA of DJ-1 gene is 570 bp, and encoding a DJ-1 protein containing 189 amino acids, with a molecular weight of ~20 kDa. The DJ-1 gene is highly conserved in evolution, the homology of human and monkey DJ-1 gene is up to 98&#x00025; and the homology to mouse is 91&#x00025; (<xref rid="b2-or-32-03-1108" ref-type="bibr">2</xref>,<xref rid="b3-or-32-03-1108" ref-type="bibr">3</xref>). Formation, positive regulation of androgen receptor and the fertilization process, participation in the regulation of RNA binding complex (<xref rid="b4-or-32-03-1108" ref-type="bibr">4</xref>), and anti-oxidation, inhibition of apoptosis (<xref rid="b5-or-32-03-1108" ref-type="bibr">5</xref>). Previous studies on the DJ-1 gene were mostly on Parkinson&#x02019;s disease (PD)-related research, and they found that its mutations are related to human early-onset PD. However, some studies have found that the DJ-1 gene is closely related to tumor as well. Several studies found that DJ-1 protein overexpression is present in a variety of tumors such as breast cancer, non-small cell lung cancer, esophageal squamous cell carcinoma and prostate cancer, and this overexpression is related to proliferation, metastasis and poor prognosis of malignant tumors (<xref rid="b6-or-32-03-1108" ref-type="bibr">6</xref>&#x02013;<xref rid="b10-or-32-03-1108" ref-type="bibr">10</xref>). Currently, carcinogenic DJ-1 gene downstream molecular signaling network and transduction mechanism remain unclear, and the role of the DJ-1 gene in the tumor formation and growth process is also unclear. Kim <italic>et al</italic> found that DJ-1 expression in breast cancer specimens was negatively correlated with PTEN, while positively correlated with PKB/Akt (<xref rid="b6-or-32-03-1108" ref-type="bibr">6</xref>). Studies have also indicated that the DJ-1 gene can promote the PI3K/AKT/mTOR pathway by regulating PTEN genes, thereby enabling increased expression of a variety of detoxifying enzymes to improve the cell viability and promote cell proliferation (<xref rid="b11-or-32-03-1108" ref-type="bibr">11</xref>). Davidson <italic>et al</italic> detected PTEN protein expression levels of cancer tissues of nearly 300 cases of ovarian cancer patients with immunohistochemistry, and analyzed DJ-1 mRNA levels with RT-PCR. The results suggested that the levels of DJ-1 and PTEN were not correlated (<xref rid="b12-or-32-03-1108" ref-type="bibr">12</xref>). Therefore, whether DJ-1 is involved in regulation of PTEN remains to be confirmed with further research. In the present study, retrovirus was used for stable transfection of DJ-1 gene to laryngeal squamous carcinoma cell line SNU-46, and the cell line was screened out to compare the changes in tumor biological characteristics (proliferation, apoptosis, invasion and migration) with untreated laryngeal cancer cell lines. In the present study, we preliminarily studied the effect of DJ-1 gene overexpression on laryngeal cancer cell line SNU-46 biological activities, PI3K/AKT/mTOR pathway and PTEN protein expression.</p></sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec sec-type="materials">
<title>Materials</title>
<sec>
<title>Cell line and culture</title>
<p>Human laryngeal squamous cell carcinoma SNU-46 cells were cultured in RPMI-1640 medium containing 10&#x00025; fetal bovine serum (FBS; HyClone) and incubated in a 37&#x000B0;C, 5&#x00025; CO<sub>2</sub> humidified incubator. GP2-293 packaging cells were cultured in high glucose Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) containing 10&#x00025; FBS.</p></sec>
<sec>
<title>Biomaterials</title>
<p>pCDNA3.1(+)-DJ-1 plasmid carrying DJ-1 gene coding sequence was stored in our laboratory. pLNCX2 plasmid, pVSV-G plasmid and GP2-293 packaging cells were kindly donated by Dr Lei Jinju from the Sun Yat-sen University Cancer Center (SYSUCC). Restriction endonucleases <italic>Not</italic>I and <italic>Xho</italic>I were purchased from Fermentas (USA), DJ-1 primers were purchased from Guangzhou RiboBio Co., DJ-1 monoclonal antibody was purchased from Abcam Co., GAPDH monoclonal antibody was purchased from BioWorld Co., HRP-labeled goat anti-mouse monoclonal antibody was purchased from Santa Cruz Co., AKT, phospho-Akt (Ser473), mTOR, phospho-mTOR (Ser2448) and PTEN antibody were purchased from Cell Signaling Technology, Inc.</p></sec></sec>
<sec>
<title>Methods</title>
<sec>
<title>Vector construction</title>
<p>Using PCR method, according to the DJ-1 gene sequence information and planned inserting restriction endonuclease gene site sequence, we designed the coding region amplification primers. pCDNA3.1(+)-DJ-1 plasmid was used as template to amplify its coding sequence (CDS) by PCR. The gene sequence and vector sequence were analyzed. Two restriction endonucleases <italic>Not</italic>I and <italic>Xho</italic>I may be used to clone destination gene fragment into the vector. Designed primers were: F, 5&#x02032;CCGCTCGAGACCATGGCTTC CAAAAGAGCTCTGGTCAT3&#x02032; and R, 5&#x02032; ATTTGCGGCCG CCTAGTCTTTAAGAACAAGTGGAGCCTTCA3&#x02032; (primer synthesis, Shanghai Sangon Co., Ltd.). The PCR products were purified by gel electrophoresis and recovered for plasmid splicing. Gel extraction kit was the product of Qiagen Co. (USA). Restriction endonucleases <italic>Not</italic>I and <italic>Xho</italic>I were used for double digestion of the above PCR product and pLNCX2 plasmids, followed by agarose gel electrophoresis, purification and recovery of the digested products. DNA Ligation kit (Takara) was used for connection. The connected plasmids were used to transform DH-5&#x003B1; competent <italic>E. coli</italic>, followed by expanding culture, extraction and sequencing detection.</p></sec>
<sec>
<title>Transfection</title>
<p>The transfection was performed with the Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer&#x02019;s protocol.</p></sec>
<sec>
<title>Retroviral packaging</title>
<p>The day before transfection, GP2-293 cells were inoculated in a 10 cm petri dish. High glucose DMEM medium containing 10&#x00025; fetal calf serum was used for culture and transfection began at 50&#x00025; cell fusion. Six micrograms of each pVSV-G and pLNCX2-DJ-1 plasmid was added to 1.5 ml Opti-MEM serum-free medium, and then 20 &#x003BC;l Lipofectamine 2000 liposome transfection reagent was added to 1.5 ml Opti-MEM serum-free medium. The two liquids were placed at room temperature for 5 min, and then gently mixed together. The mixture was stored for 20 min and was added to GP2-293 cells. Six hours later, the medium was changed and 10 ml fresh high glucose DMEM medium containing 10&#x00025; FBS was added. After 48 h, GP2-293 cell culture supernatant in the 10 cm petri dish was drawn and filtered through 0.45 &#x003BC;m filter to remove cell debris and other impurities, and it was stored at &#x02212;80&#x000B0;C. The same method was used to transfect pVSV-G and pLNCX2 empty vector plasmid to obtain empty vector virus of the control group, which was stored at &#x02212;80&#x000B0;C.</p></sec>
<sec>
<title>Retroviral infection of SNU-46 cells</title>
<p>Twenty four hours before infection, the SNU-46 cells were inoculated in 10 cm petri dishes, with inoculation density of ~50&#x00025;. Polybrene (8 &#x003BC;g/ml) was added to 5 ml virus-containing supernatant which was added to SNU-46 cells. After 6 h, the culture medium and virus-containing supernatant in SNU-46 cells were discarded. RPMI-1640 medium (5 ml) and 5 ml viral-containing supernatant (8 &#x003BC;g/ml of polybrene added) were added again. After 6 h, RPMI-1640 medium containing 10&#x00025; FBS was replaced. The above method was applied to the infection of SNU-46 cells with retrovirus carrying DJ-1 gene and empty vector virus of the control group.</p></sec>
<sec>
<title>Stable cell line selection</title>
<p>Cells were cultured continuously at 37&#x000B0;C for 48 h. Antibiotic G418 (200 &#x003BC;g/ml) was initially used to screen the positive clones. After 10&#x02013;12 days, cells were maintained continuously in the medium with G418 (100 &#x003BC;g/ml), until the cell colony was macroscopic. The surviving cells from G418 screening were prepared to cell suspensions. The cells were counted and diluted with cell culture medium to 1/10 &#x003BC;l. G418 screening medium prepared according to the best screening concentration was added to a 96-well plate, with 150 &#x003BC;l/well, then cell suspension was added, with 10 &#x003BC;l/hole. Twenty-four hours later, the plate was observed under a microscope. The well which had only one living cell was selected and labelled. Standard RPMI-1640 medium containing 15&#x00025; FBS medium was replaced once every two days. When single cell was proliferated to ~100 cells, the cells in the wells were moved to a 48-well plate for continued culture after digestion. After proliferation, cells were moved to a 24-well plate, and so on, so cells were cultured progressively to obtain G418-resistant cell lines after several successful and stable transfections.</p></sec>
<sec>
<title>CCK-8 assay</title>
<p>Cell Counting Kit-8 from Biyuntian Company was used in the experiment. Cell proliferation in each group was detected at 24, 48 and 72 h, respectively, after cells were inoculated. The inoculated cells were suspended in 96-well plates, with 100 &#x003BC;l/well, and each well contained 2,000 cells. The plates were pre-cultured in an incubator (37&#x000B0;C, 5&#x00025; CO<sub>2</sub> overnight stable condition). During the experiment to determine the number of cells, 10 &#x003BC;l CCK-8 solution was added to each well, and the plate was incubated for 1.5 h. The absorbance at 450 nm (OD) was measured by a microplate reader, and a cell growth curve was drawn with time as the abscissa and absorbance values as the vertical.</p></sec>
<sec>
<title>In vitro migration and invasion assays</title>
<p>For the Transwell migration or invasion assays, cells in 0.2 ml RPMI-1640 without FBS were placed on the top chamber of each insert (BD Biosciences, Franklin Lakes, NJ, USA) with or without 40 &#x003BC;l of 1 mg/ml Matrigel. The lower chamber was filled with 600 &#x003BC;l of RPMI-1640 medium with 10&#x00025; FBS to act as the nutritional attractant. Twenty-four hours later, the migrant cells that had attached to the lower surface were fixed with 20&#x00025; methanol and stained for 20 min with crystal violet. The membranes were then carved and embedded under cover slips with the cells on the top. Cells in three different fields of view at &#x000D7;100 magnification were counted and expressed as the average number of cells per field of view. All assays were performed in triplicate.</p></sec>
<sec>
<title>Real-time RT-PCR</title>
<p>Real-time RT-PCR was performed to detect the relative level of DJ-1 transcription and mature miRNA. Briefly, complement DNA (cDNA) was generated through reverse transcription using M-MLV reverse transcriptase (Promega) with 1 &#x003BC;g of total RNA. This cDNA product was used to amplify the DJ-1 gene. The PCR conditions were: 95&#x000B0;C for 5 min, followed by 40 cycles of 95&#x000B0;C for 15 sec, 60&#x000B0;C for 15 sec and 72&#x000B0;C for 32 sec.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>The cells were lysed with RIPA lysis buffer and the proteins were harvested. All proteins were resolved on a 10&#x00025; SDS denatured polyacrylamide gel and then transferred onto a nitrocellulose membrane. The membranes were incubated overnight at 4&#x000B0;C with mouse monoclonal to PARK7/DJ1 (Abcam, USA) and rabbit monoclonal anti-human GAPDH, PTEN, AKT/phospho-Akt (Ser473), mTOR/phospho-mTOR (Ser2448) (Cell Signaling Technology, Inc.). Goat anti-mouse IgG-HRP (1:1,000; Jackson Co.) and goat anti-rabbit IgG-HRP (1:500; Santa Cruz Inc.) were used for secondary antibody and DAB coloring.</p></sec>
<sec>
<title>Flow cytometry</title>
<p>Apoptosis detection kit from Nanjing Kaiji Co. was used in the experiment. Cells were collected with EDTA-free trypsin and washed twice with PBS, followed by centrifugation (2,000 rpm) for 5 min. Binding buffer (500 &#x003BC;l) was added for cell suspension. Annexin V-EGFP (5 &#x003BC;l) was added and mixed well, followed by addition of 5 &#x003BC;l propidium iodide and mixed well. The mixture was reacted at room temperature for 5&#x02013;15 min in a dark environment, followed by detection with flow cytometry, excitation wavelength Ex, 488 nm; emission wavelength Em, 530 nm. Green fluorescence of Annexin V-EGFP was detected with FITC channel (FL1); PI red fluorescence was detected by PI channel (FL2 or FL3). Fluorescence compensation adjustment; normal untreated cells were used as control for fluorescence compensation adjustment to remove spectra overlap and set the cross gate position.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>All measurement data are expressed as the means &#x000B1; SD. Differences among groups were analyzed by one-way ANOVA and Student-Newman-Keuls (SNK) q-test using SPSS 12.0 software for Windows. Statistical significance was defined as having a p-value &lt;0.05.</p></sec></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Double enzyme digestion of the recombinant plasmid pLNCX2-DJ-1</title>
<p>The recombinant plasmid pLNCX2-DJ-1 was transformed into competent <italic>E. coli</italic>, and then the plasmid was extracted after shaking bacteria. <italic>Not</italic>I, <italic>Xho</italic>I double digestion was performed on the exacted plasmid. The digestion result was detected with 1&#x00025; agarose gel electrophoresis. There was clearly visible strip for the double digestion products near 600 bp (<xref rid="f1-or-32-03-1108" ref-type="fig">Fig. 1</xref>). Forward sequencing was carried out for the recombinant plasmid pLNCX2-DJ-1 according to pLNCX2 carrier up and downstream primer sequences. BLAST alignment was performed for the sequencing results (Beijing Liuhehua Biotechnology) with DJ-1 sequence in NCBI and matching degree was 100&#x00025;.</p></sec>
<sec>
<title>Determination of G418 screening concentration</title>
<p>After 10 concentration gradient tests of G418 in 100&#x02013;1,000 &#x003BC;g/ml, the minimum G418 concentration in which cells died within 10 days was 100 &#x003BC;g/ml. Therefore, the optimum concentration of G418 screening was 100 &#x003BC;g/ml.</p></sec>
<sec>
<title>Screening of laryngeal carcinoma cell lines of stably transfected DJ-1 protein overexpression</title>
<p>SNU-46 cells infected with the virus were screened in a normal medium without G418. As shown in <xref rid="f2-or-32-03-1108" ref-type="fig">Fig. 2</xref>, cells infected with retroviral that did not obtain stable transfection gradually died without G418 resistance, and cells that stably transfected had G418 resistance and continued proliferation. Cells which obtained G418 resistance continued to culture in the screening of antibiotics environment to make a large amount. Then, several monoclonal cell lines were selected with the limiting dilution method. Three monoclonal cell lines that were infected with retrovirus carrying DJ-1 gene and screened through G418 were selected and termed SNU-46-D1 (<xref rid="f3-or-32-03-1108" ref-type="fig">Fig. 3</xref>), SNU-46-D2 (<xref rid="f4-or-32-03-1108" ref-type="fig">Fig. 4</xref>) and SNU-46-D3 (<xref rid="f5-or-32-03-1108" ref-type="fig">Fig. 5</xref>). One monoclonal cell line which was infected with empty vector retrovirus not carrying gene DJ-1 and screened after G418 was selected and termed SNU-46-CON (<xref rid="f6-or-32-03-1108" ref-type="fig">Fig. 6</xref>). <xref rid="f7-or-32-03-1108" ref-type="fig">Fig. 7</xref> shows untreated normal SNU-46 cells.</p></sec>
<sec>
<title>qRT-PCR detection of DJ-1 mRNA expression levels of monoclonal cell lines</title>
<p>RNA sample (1 &#x003BC;l) was obtained for 1&#x00025; agarose gel electrophoresis 80 V &#x000D7; 20 min. Total RNA 5s, 18s and 28s rRNA bands were observed by gel imaging system. Three complete bands proved a complete extraction of total RNA (<xref rid="f8-or-32-03-1108" ref-type="fig">Fig. 8</xref>). DJ-1 gene expression in five types of samples is shown in <xref rid="f9-or-32-03-1108" ref-type="fig">Fig. 9</xref>, and DJ-1 gene expression levels of SNU-46-D1, SNU-46-D2 and SNU-46-D3 are significantly higher than SNU-46-CON and SNU-46 cells.</p></sec>
<sec>
<title>Western blot detection of DJ-1 protein expression levels in each monoclonal cell line</title>
<p>The total protein was extracted after SNU-46-D1, SNU-46-D2, SNU-46-D3, SNU-46-CON and SNU-46 cell proliferation, and DJ-1 protein expression levels of monoclonal cell lines were detected by western blotting. The results showed that DJ-1 protein expression of SNU-46-D1 cells was significantly higher than other cell groups (<xref rid="f10-or-32-03-1108" ref-type="fig">Fig. 10</xref>). SNU-46-D1 cell protein was extracted again and SNU-46-CON and SNU-46 cells were used as control. Western blotting was repeated twice to verify if DJ-1 protein expression of SNU-46-D1 was higher than normal SNU-46 and SNU-46-CON empty vector control cells (<xref rid="f11-or-32-03-1108" ref-type="fig">Fig. 11</xref>). The results of the three repeats were subjected to grey and statistical analysis, and it showed the relative DJ-1 protein expression of SNU-46-D1 cells was 1.969&#x000B1;0.137. There was a significant difference (<sup>*</sup>p&lt;0.001; <sup>**</sup>p&lt;0.001; <xref rid="f12-or-32-03-1108" ref-type="fig">Fig. 12</xref>) compared to SNU-46 (0.624&#x000B1;0.079) and SNU-46-CON empty vector control cells (0.783&#x000B1;0.279), while the relative DJ-1 protein expression levels of SNU-46 and SNU-46-CON empty vector control cells showed no significant difference (<sup>***</sup>p=0.081). Compared with the blank control SNU-46 cells, DJ-1 protein expression levels increased 2.16-fold, therefore monoclonal cell line SNU-46-D1 of DJ-1 protein overexpression was successfully constructed.</p></sec>
<sec>
<title>Overexpression of DJ-1 protein reduces SNU-46 cell apoptosis rate</title>
<p><xref rid="f13-or-32-03-1108" ref-type="fig">Fig. 13</xref> shows results of the apoptosis rate of three cell lines using flow cytometry with the Annexin V/PI apoptosis kit. There was a significant difference (p&lt;0.05) of the apoptotic cell rate among SNU-46-D1, SNU-46-CON and SNU-46. Combining multiple comparison results showed the apoptotic ratio of SNU-46-D1 cell line (3.533&#x000B1;5.167&#x00025;) was significantly lower than that of SNU-46 (16.397&#x000B1;5.447&#x00025;) and SNU-46-CON cell lines (16.980&#x000B1;4.124&#x00025;) (<sup>*</sup>p=0.019; <sup>**</sup>p=0.016). There was no statistical difference between cell line SNU-46 apoptosis rate and cell line SNU-46-CON (<sup>***</sup>p=0.890).</p></sec>
<sec>
<title>Overexpression of DJ-1 protein promotes SNU-46 cell proliferation</title>
<p>Results of CCK-8 detection of cell proliferation are shown in <xref rid="f14-or-32-03-1108" ref-type="fig">Fig. 14</xref>. Forty-eight and 72 h after inoculation, SNU-46-D1 cell proliferation rate was higher than SNU-46 and SNU-46-CON cells (48 h, 0.834&#x000B1;0.336 vs. 0.676&#x000B1;0.112, <sup>*</sup>p&lt;0.001; 0.834&#x000B1;0.336 vs. 0.694&#x000B1;0.210, <sup>*</sup>p&lt;0.001; 72 h, 0.965&#x000B1;0.177 vs. 0.830&#x000B1;0.172, <sup>**</sup>p&lt;0.001; 0.965&#x000B1;0.177 vs. 0.831&#x000B1;0.180, <sup>**</sup>p&lt;0.001).</p></sec>
<sec>
<title>Overexpression of DJ-1 protein enhances SNU-46 cell invasion and migration</title>
<p>As shown in <xref rid="f15-or-32-03-1108" ref-type="fig">Fig. 15</xref>, SNU-46-D1 cell invasion force was higher than SNU-46 and SNU-46-CON cells (165.7&#x000B1;13.6 vs. 100.0&#x000B1;17.4, <sup>*</sup>p=0.001; 165.7&#x000B1;13.6 vs. 103.0&#x000B1;7.6, <sup>*</sup>p=0.001); as shown in <xref rid="f16-or-32-03-1108" ref-type="fig">Fig. 16</xref>, SNU-46-D1 cell migration was higher than SNU-46 and SNU-46-CON cells (207.3&#x000B1;13.1 vs. 175.3&#x000B1;13.3, <sup>*</sup>p=0.036; 207.3&#x000B1;13.1 vs. 173.0&#x000B1;12.5, <sup>*</sup>p=0.027).</p></sec>
<sec>
<title>Western blot detection of changes in p-AKT, AKT, p-mTOR, mTOR, PTEN protein expression levels after DJ-1 overexpression</title>
<p>As shown in <xref rid="f17-or-32-03-1108" ref-type="fig">Figs. 17</xref>&#x02013;<xref rid="f19-or-32-03-1108" ref-type="fig">19</xref>, p-AKT protein expression levels improved after overexpression of DJ-1, while AKT protein expression did not change. p-mTOR protein expression increased and mTOR protein expression did not change. PTEN protein expression decreased.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Laryngeal cancer is ranked second in the incidence of head and neck tumors, and the most common histological type is squamous cell carcinoma (<xref rid="b13-or-32-03-1108" ref-type="bibr">13</xref>&#x02013;<xref rid="b15-or-32-03-1108" ref-type="bibr">15</xref>). Currently, the overall 5-year survival rate is still hovering at 55&#x02013;65&#x00025; (<xref rid="b16-or-32-03-1108" ref-type="bibr">16</xref>&#x02013;<xref rid="b21-or-32-03-1108" ref-type="bibr">21</xref>). The molecular biological mechanisms of the pathogenesis of laryngeal cancer remain to be explored. Previous studies found that there was overexpression of DJ-1 of laryngeal tissue and Hep-2 cells, and poorly differentiated laryngeal cancer had higher DJ-1 expression level than well differentiated laryngeal cancer. Silencing DJ-1 gene can effectively inhibit the proliferation of Hep-2 cells, inducing apoptosis (<xref rid="b22-or-32-03-1108" ref-type="bibr">22</xref>). However, the effect of DJ-1 gene overexpression in laryngeal cancer cells on the biological behavior of laryngeal tumor cells has not been reported. Also, the effect of DJ-1 gene overexpression on laryngeal cancer proliferation, migration, invasion, apoptosis and other biological characteristics of the tumor cells remains unclear. The signaling pathway through which the DJ-1 gene mediates to affect laryngeal cancer is also unknown. Therefore, on the basis of previous studies, we stably transfected DJ-1 gene through retrovirus to laryngeal squamous cell carcinoma SNU-46 cell line and successfully screened out laryngeal squamous cell lines with stable overexpression of DJ-1 protein. The differences of biological characteristics between laryngeal carcinoma cell line SNU-46-D1 with DJ-1 gene overexpression and normal laryngeal cancer cells was detected, thereby we preliminarily studied the role of DJ-1 overexpression in cell proliferation, invasion, migration, apoptosis, and established a research basis for future studies in nude mice.</p>
<p>The early pre-experiment showed that the stable transfection efficiency of SNU-46 laryngeal squamous cell line with electroporation and lipofection is very low. In the present study, retrovirus pLNCX2-DJ-1 vector carrying DJ-1 gene was constructed; pVSV-G packaging plasmids and GP2-293 packaging cells were used to successfully package viral particles carrying DJ-1 gene, which in turn infected SNU-46 cells to achieve stable DJ-1 gene expression in SNU-46 laryngeal cancer cells. Since the pLNCX2-DJ-1 vector also contains the neo gene in addition to DJ-1 gene sequence, successfully transfected cells obtained resistance to antibiotic G418. Therefore, cells that were not successfully transfected could be eliminated through G418 screening. In the present study, a laryngeal carcinoma cell line with stable overexpression of DJ-1 protein was successfully screened out, SNU-46-D1. After western blotting, DJ-1 protein expression increased 2.16-fold compared to normal SNU-46 cells. We also screened an SNU-46 cell line as the empty vector control (SNU-46-CON), of which DJ-1 expression level was no different to untreated cells.</p>
<p>Apoptosis is a suicide mechanism of cell active participation (<xref rid="b22-or-32-03-1108" ref-type="bibr">22</xref>) and evasion apoptosis is one of the basic characteristics of tumor cells. The defect of apoptotic signaling pathway is widespread in cancer. In the present study, after flow cytometry detection with Annexin V/PI apoptosis kit, the results showed that the apoptosis rate of SNU-46-D1 was significantly lower than the rates of cell lines SNU-46 and SNU-46-CON, suggesting that overexpression of the DJ-1 gene inhibited apoptosis of laryngeal cancer cells. Previous reports showed that DJ-1 gene silencing can induce apoptosis of laryngeal cancer Hep-2 cells (<xref rid="b23-or-32-03-1108" ref-type="bibr">23</xref>). Therefore, the DJ-1 gene may play a role in inhibiting apoptosis of laryngeal cancer cells to prolong laryngeal cell survival time and provide the conditions for the growth of laryngeal cancer cells. CCK-8 detection of cell proliferation showed that SNU-46-D1 cell proliferation rate was faster than normal SNU-46 cells. The difference was statistically significant. This suggests that the DJ-1 gene plays a facilitating role in the proliferation of SNU-46 cells. After detecting the invasion and migration ability of SNU-46 laryngeal cancer cells and SNU-46-D1 cells with stably transfected DJ-1 protein overexpression by Transwell chamber experiments, we found that after stable transfection by up to 2&#x000D7; the DJ-1 protein expression, invasion of SNU-46-D1 cells increased by ~65&#x00025; compared to normal SNU-46, and migration increased by ~20&#x00025;. This suggests that overexpression of DJ-1 protein can enhance the ability of laryngeal cancer cell invasion and migration. Through stable transfection for laryngeal cells SNU-46 to overexpress DJ-1 protein, the apoptosis rate decreased, proliferation rate increased, invasion and migration capabilities also improved. This suggests that the DJ-1 gene may play a role in laryngeal cancer genes similar to oncogenes, and laryngeal DJ-1 gene high expression may lead to increased laryngeal malignancy, reducing the prognosis. Zhu <italic>et al</italic> used immunohistochemistry to detect tumor tissues of 7l postoperative patients with laryngeal squamous cell carcinoma and laryngeal mucosa of 9 patients with non-laryngeal who were treated between January 1995 and January 2006. After analyzing the relationship between DJ-1 protein expression and clinicopathological features, they found DJ-l protein expression levels in laryngeal squamous cell carcinoma were higher than in normal laryngeal mucosa, and survival rates may be lower for laryngeal cancer patients with higher levels of DJ-1 protein expression (<xref rid="b23-or-32-03-1108" ref-type="bibr">23</xref>). In 2012, Zhu <italic>et al</italic> also found that the DJ-l protein overexpression in tumor tissue of supraglottic laryngeal squamous cell carcinoma was associated with lymph node metastasis. Lymph node metastasis has higher incidence for patients with high DJ-1 protein expression. The five-year survival rate of patients with high DJ-1 protein expression in supraglottic laryngeal squamous cell carcinoma is also lower (53.9 vs. 88.0&#x00025;; p=0.007; log-rank test) (<xref rid="b24-or-32-03-1108" ref-type="bibr">24</xref>). The data on DJ-1 expression levels and clinical tumor malignancy and prognosis are consistent with our conclusion regarding the impact of DJ-1 protein on laryngeal carcinoma cell SNU-46 functions. The DJ-1 gene may play a role similar to oncogenes in laryngeal carcinoma, and can inhibit apoptosis. The DJ-1 gene can extend the survival time of laryngeal cancer cells, and provide conditions for laryngeal cancer cell growth. At the same time, the DJ-1 gene can promote the proliferation of laryngeal cancer cells, resulting in the rapid expansion of laryngeal cancer cells and accelerated tumor growth. More importantly, the DJ-1 gene can enhance the ability of laryngeal cancer cell invasion and migration. It may lead to tumor lymph node metastasis and distant metastasis, resulting in an adverse impact on the prognosis of patients.</p>
<p>Through stable transfection of DJ-1 gene to SNU-46 cells and detection of changes in the biological characteristics of the tumor cells, this study preliminarily showed the DJ-1 gene can inhibit tumor cell apoptosis and promote proliferation, migration and invasion of tumor cells. Regarding the molecular pathway mechanism which leads to changes in the biological characteristics of these tumors, current studies support that DJ-1 protein affects biological properties of the cells mainly through negative regulation of PTEN (phosphatase and tensin homolog) expression. Kim <italic>et al</italic> found DJ-1 expression in breast cancer specimens was negatively correlated with PTEN and positively correlated with PKB/Akt (<xref rid="b6-or-32-03-1108" ref-type="bibr">6</xref>). Zhu <italic>et al</italic> found that the DJ-l protein overexpression in tumor tissue of supraglottic laryngeal squamous cell carcinoma was accompanied by low expression of PTEN (<xref rid="b24-or-32-03-1108" ref-type="bibr">24</xref>). PTEN is a tumor suppressor that can inhibit the phosphorylation of PIP2 to reduce the PIP3 generation and ultimately reduce PKB/Akt activation and inhibit cell growth (4.) DJ-1 protein overexpression can lead to reduced expression of PTEN, thereby removing the inhibition of PTEN on cell growth, and promoting cell growth and proliferation. Studies have also suggested that the DJ-1 gene can promote the PI3K/AKT/mTOR pathway in lung cancer cells by regulating PTEN gene, thereby enabling increased expression of a variety of detoxifying enzymes and promoting cell proliferation (<xref rid="b11-or-32-03-1108" ref-type="bibr">11</xref>). Regarding the approach of DJ-1 gene regulation on PTEN, some researchers believe the DJ-1 gene may be involved in the regulation of PTEN gene through the PI3K-AKT/PKB signaling pathway to act on c-myc (<xref rid="b25-or-32-03-1108" ref-type="bibr">25</xref>). Other researchers consider that DJ-1 may regulate PTEN through their redox-sensitive molecular chaperone activity (<xref rid="b26-or-32-03-1108" ref-type="bibr">26</xref>). In addition, studies have also found that DJ-1 can activate hypoxia-inducible factor l (HIF1) in the absence of oxygen, and has a crucial role in maintaining the stability of HIF1, therefore DJ-1 is resistant to hypoxia-mediated apoptosis, protecting cells under hypoxia. Meanwhile DJ-1 can also regulate activity of AMP protein kinase (AMPK) which controls cell metabolism. This regulation is more obvious under a hypoxic environment (<xref rid="b27-or-32-03-1108" ref-type="bibr">27</xref>). These studies suggest that the laryngeal apoptosis rate decreased after the overexpression of DJ-1 most likely since DJ-1 can help tumor cells to evade apoptosis incurred by an anoxic environment.</p>
<p>Our previous studies showed Akt and mTOR overexpression in laryngeal cancer are correlated with prognosis, and are negatively correlated with tumor differentiation. The recurrent rate of patients with overexpression of downstream gene EIF4E on the signaling pathway in laryngeal tissue and overexpression of eIF4E on surgical margins is high, and the prognosis is poor. mTOR inhibitor rapamycin can stop Hep-2 cells in the G1 phase, inhibiting their proliferation and promoting apoptosis. Joint application of rapamycin and cisplatin can have a synergistic effect (<xref rid="b28-or-32-03-1108" ref-type="bibr">28</xref>). LSCC DJ-1 protein overexpression and Akt/mTOR overexpression often occur simultaneously. Previous studies have shown DJ-1 may mediate the PI3K/AKt/mTOR signaling pathway to affect the survival of a variety of tumor cells (<xref rid="b6-or-32-03-1108" ref-type="bibr">6</xref>,<xref rid="b27-or-32-03-1108" ref-type="bibr">27</xref>). Through the construction of SNU-46 laryngeal squamous cell line of stably overexpressed DJ-1 protein, and detection of expression level changes of proteins associated with the PI3K/AKt/mTOR signaling pathway between this cell and normal SNU-46 cell line, this study provided preliminary validation that DJ-1 may affect the biological characteristics of laryngeal cancer cells through the PI3K/AKt/mTOR signaling pathway.</p>
<p>Through the construction of stable overexpression of DJ-1 protein in laryngeal carcinoma cell lines, the present study established a foundation for subsequent <italic>in vivo</italic> experiments in nude mice. We will carry out more comprehensive studies on SNU-46-D1 cell lines with stable overexpression of the DJ-1 gene to gain more in-depth understanding of the function of DJ-1 gene in the occurrence and development of laryngeal cancer and cell signaling pathways mediated by DJ-1 gene, thereby laying the foundations for the assessment of the feasibility and efficacy of the DJ-1 gene as a new therapeutic target for laryngeal cancer.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the National Natural Science Foundation of China (81072224), the Young Faculty Cultivation Project of Sun Yat-sen University (10ykpy10), and the Science and Technology Planning Project of Guangdong Province (2009B030801109).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-32-03-1108"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagakubo</surname><given-names>D</given-names></name><name><surname>Taira</surname><given-names>T</given-names></name><name><surname>Kitaura</surname><given-names>H</given-names></name><etal/></person-group><article-title>DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with <italic>ras</italic></article-title><source>Biochem Biophys Res Commun</source><volume>231</volume><fpage>509</fpage><lpage>513</lpage><year>1997</year></element-citation></ref>
<ref id="b2-or-32-03-1108"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annesi</surname><given-names>G</given-names></name><name><surname>Savettieri</surname><given-names>G</given-names></name><name><surname>Pugliese</surname><given-names>P</given-names></name><etal/></person-group><article-title>DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex</article-title><source>Ann Neurol</source><volume>58</volume><fpage>803</fpage><lpage>807</lpage><year>2005</year></element-citation></ref>
<ref id="b3-or-32-03-1108"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Hague</surname><given-names>S</given-names></name><etal/></person-group><article-title>L166P mutant DJ-1, causative for recessive Parkinson&#x02019;s disease, is degraded through the ubiquitin-proteasome system</article-title><source>J Biol Chem</source><volume>278</volume><fpage>36588</fpage><lpage>36595</lpage><year>2003</year></element-citation></ref>
<ref id="b4-or-32-03-1108"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinat</surname><given-names>C</given-names></name><name><surname>Shendelman</surname><given-names>S</given-names></name><name><surname>Jonason</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism</article-title><source>PLoS Biol</source><volume>2</volume><fpage>e327</fpage><year>2004</year></element-citation></ref>
<ref id="b5-or-32-03-1108"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Troncoso</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress</article-title><source>Hum Mol Genet</source><volume>14</volume><fpage>71</fpage><lpage>84</lpage><year>2005</year></element-citation></ref>
<ref id="b6-or-32-03-1108"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>RH</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>DJ-1, a novel regulator of the tumor suppressor PTEN</article-title><source>Cancer Cell</source><volume>7</volume><fpage>263</fpage><lpage>273</lpage><year>2005</year></element-citation></ref>
<ref id="b7-or-32-03-1108"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKeigan</surname><given-names>JP</given-names></name><name><surname>Clements</surname><given-names>CM</given-names></name><name><surname>Lich</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDI&#x003B1;</article-title><source>Cancer Res</source><volume>63</volume><fpage>6928</fpage><lpage>6934</lpage><year>2003</year></element-citation></ref>
<ref id="b8-or-32-03-1108"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hod</surname><given-names>Y</given-names></name></person-group><article-title>Differential control of apoptosis by DJ-1 in prostate benign and cancer cells</article-title><source>J Cell Biochem</source><volume>92</volume><fpage>1221</fpage><lpage>1233</lpage><year>2004</year></element-citation></ref>
<ref id="b9-or-32-03-1108"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Naour</surname><given-names>F</given-names></name><name><surname>Misek</surname><given-names>DE</given-names></name><name><surname>Krause</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer</article-title><source>Clin Cancer Res</source><volume>7</volume><fpage>3328</fpage><lpage>3335</lpage><year>2001</year></element-citation></ref>
<ref id="b10-or-32-03-1108"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Shiina</surname><given-names>H</given-names></name><name><surname>Urakami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy</article-title><source>Clin Cancer Res</source><volume>12</volume><fpage>6116</fpage><lpage>6124</lpage><year>2006</year></element-citation></ref>
<ref id="b11-or-32-03-1108"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Pintilie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dysregulated PTEN-PKB and negative receptor status in human breast cancer</article-title><source>Int J Cancer</source><volume>104</volume><fpage>195</fpage><lpage>203</lpage><year>2003</year></element-citation></ref>
<ref id="b12-or-32-03-1108"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Hadar</surname><given-names>R</given-names></name><name><surname>Schlossberg</surname><given-names>A</given-names></name><etal/></person-group><article-title>Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma</article-title><source>Hum Pathol</source><volume>39</volume><fpage>87</fpage><lpage>95</lpage><year>2008</year></element-citation></ref>
<ref id="b13-or-32-03-1108"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>EA</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group><article-title>Laryngeal cancer: diagnosis and preoperative work-up</article-title><source>Otolaryngol Clin North Am</source><volume>41</volume><fpage>673</fpage><lpage>695</lpage><year>2008</year></element-citation></ref>
<ref id="b14-or-32-03-1108"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><volume>55</volume><fpage>74</fpage><lpage>108</lpage><year>2005</year></element-citation></ref>
<ref id="b15-or-32-03-1108"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adelstein</surname><given-names>DJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Adams</surname><given-names>GL</given-names></name><etal/></person-group><article-title>An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer</article-title><source>J Clin Oncol</source><volume>21</volume><fpage>92</fpage><lpage>98</lpage><year>2003</year></element-citation></ref>
<ref id="b16-or-32-03-1108"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>HT</given-names></name><name><surname>Porter</surname><given-names>K</given-names></name><name><surname>Karnell</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival</article-title><source>Laryngoscope</source><volume>116</volume><fpage>1</fpage><lpage>13</lpage><year>2006</year></element-citation></ref>
<ref id="b17-or-32-03-1108"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denis</surname><given-names>F</given-names></name><name><surname>Garaud</surname><given-names>P</given-names></name><name><surname>Bardet</surname><given-names>E</given-names></name><etal/></person-group><article-title>Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma</article-title><source>J Clin Oncol</source><volume>22</volume><fpage>69</fpage><lpage>76</lpage><year>2004</year></element-citation></ref>
<ref id="b18-or-32-03-1108"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forastiere</surname><given-names>AA</given-names></name><name><surname>Maor</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy</article-title><source>J Clin Oncol</source><volume>24</volume><issue>Suppl 18</issue><fpage>5517</fpage><year>2006</year></element-citation></ref>
<ref id="b19-or-32-03-1108"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiwert</surname><given-names>TY</given-names></name><name><surname>Cohen</surname><given-names>EE</given-names></name></person-group><article-title>State-of-the-art management of locally advanced head and neck cancer</article-title><source>Br J Cancer</source><volume>92</volume><fpage>1341</fpage><lpage>1348</lpage><year>2005</year></element-citation></ref>
<ref id="b20-or-32-03-1108"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brockstein</surname><given-names>B</given-names></name><name><surname>Haraf</surname><given-names>DJ</given-names></name><name><surname>Rademaker</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience</article-title><source>Ann Oncol</source><volume>15</volume><fpage>1179</fpage><lpage>1186</lpage><year>2004</year></element-citation></ref>
<ref id="b21-or-32-03-1108"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutter</surname><given-names>J</given-names></name><name><surname>Ozsahin</surname><given-names>M</given-names></name><name><surname>Monnier</surname><given-names>P</given-names></name><name><surname>Stupp</surname><given-names>R</given-names></name></person-group><article-title>Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma</article-title><source>Eur Arch Otorhinolaryngol</source><volume>262</volume><fpage>1</fpage><lpage>7</lpage><year>2005</year></element-citation></ref>
<ref id="b22-or-32-03-1108"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>JF</given-names></name><name><surname>Wyllie</surname><given-names>AH</given-names></name><name><surname>Currie</surname><given-names>AR</given-names></name></person-group><article-title>Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics</article-title><source>Br J Cancer</source><volume>26</volume><fpage>239</fpage><lpage>257</lpage><year>1972</year></element-citation></ref>
<ref id="b23-or-32-03-1108"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Lei</surname><given-names>WB</given-names></name><etal/></person-group><article-title>DJ-1: a novel independent prognostic marker for survival in glottic squamous cell carcinoma</article-title><source>Cancer Sci</source><volume>101</volume><fpage>1320</fpage><lpage>1325</lpage><year>2010</year></element-citation></ref>
<ref id="b24-or-32-03-1108"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Lei</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma</article-title><source>J Exp Clin Cancer Res</source><volume>31</volume><fpage>94</fpage><year>2012</year></element-citation></ref>
<ref id="b25-or-32-03-1108"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitaram</surname><given-names>RT</given-names></name><name><surname>Cairney</surname><given-names>CJ</given-names></name><name><surname>Grabowski</surname><given-names>P</given-names></name><etal/></person-group><article-title>The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma</article-title><source>Int J Cancer</source><volume>125</volume><fpage>783</fpage><lpage>790</lpage><year>2009</year></element-citation></ref>
<ref id="b26-or-32-03-1108"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shendelman</surname><given-names>S</given-names></name><name><surname>Jonason</surname><given-names>A</given-names></name><name><surname>Martinat</surname><given-names>C</given-names></name><etal/></person-group><article-title>DJ-1 is a redox-dependent molecular chaperone that inhibits &#x003B1;-synuclein aggregate formation</article-title><source>PLoS Biol</source><volume>2</volume><fpage>e362</fpage><year>2004</year></element-citation></ref>
<ref id="b27-or-32-03-1108"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasseur</surname><given-names>S</given-names></name><name><surname>Afzal</surname><given-names>S</given-names></name><name><surname>Tardivel-Lacombe</surname><given-names>J</given-names></name><etal/></person-group><article-title>DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses</article-title><source>Proc Natl Acad Sci USA</source><volume>106</volume><fpage>1111</fpage><lpage>1116</lpage><year>2009</year></element-citation></ref>
<ref id="b28-or-32-03-1108"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Jia</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Combined effect of rapamycin and cisplatin on survival of Hep-2 cells in vitro</article-title><source>Oncol Res</source><volume>18</volume><fpage>73</fpage><lpage>81</lpage><year>2009</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-32-03-1108" position="float">
<label>Figure 1</label>
<caption>
<p>Recombinant plasmid pLNCX2-DJ-1 double digestion.</p></caption>
<graphic xlink:href="OR-32-03-1108-g00.gif"/></fig>
<fig id="f2-or-32-03-1108" position="float">
<label>Figure 2</label>
<caption>
<p>SNU-46 cells with successful stable transfection obtain G418 resistance. (A) SNU-46 cells with successful stable transfection obtained G418 resistance and normal growth; (B) SNU-46 cells without successful stable transfection did not obtain G418 resistance; nuclear condensation or cleavage appeared and cells died.</p></caption>
<graphic xlink:href="OR-32-03-1108-g01.gif"/></fig>
<fig id="f3-or-32-03-1108" position="float">
<label>Figure 3</label>
<caption>
<p>SNU-46-D1 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g02.gif"/></fig>
<fig id="f4-or-32-03-1108" position="float">
<label>Figure 4</label>
<caption>
<p>SNU-46-D2 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g03.gif"/></fig>
<fig id="f5-or-32-03-1108" position="float">
<label>Figure 5</label>
<caption>
<p>SNU-46-D3 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g04.gif"/></fig>
<fig id="f6-or-32-03-1108" position="float">
<label>Figure 6</label>
<caption>
<p>SNU-46-CON cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g05.gif"/></fig>
<fig id="f7-or-32-03-1108" position="float">
<label>Figure 7</label>
<caption>
<p>SNU-46 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g06.gif"/></fig>
<fig id="f8-or-32-03-1108" position="float">
<label>Figure 8</label>
<caption>
<p>RNA electrophoresis. Lane 1, SNU-46-D1 total RNA; lane 2, SNU-46-D2 total RNA; lane 3, SNU-46-D3 of total RNA; lane 4, SNU-46-CON total RNA; lane 5, SNU-46 total RNA.</p></caption>
<graphic xlink:href="OR-32-03-1108-g07.gif"/></fig>
<fig id="f9-or-32-03-1108" position="float">
<label>Figure 9</label>
<caption>
<p>DJ-1 gene expression in five types of cells. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells; D2, SNU-46-D2 cells; D3, SNU-46-D3 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g08.gif"/></fig>
<fig id="f10-or-32-03-1108" position="float">
<label>Figure 10</label>
<caption>
<p>Western blot detection of DJ-1 protein expression levels of 5 cell groups. D1, SNU-46-D1 cells; D2, SNU-46-D2 cells; N, SNU-46 cells; C, SNU-46-CON cells; D3, SNU-46-D3 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g09.gif"/></fig>
<fig id="f11-or-32-03-1108" position="float">
<label>Figure 11</label>
<caption>
<p>Western blot detection of DJ-1 protein levels of SNU-46-D1 cells. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g10.gif"/></fig>
<fig id="f12-or-32-03-1108" position="float">
<label>Figure 12</label>
<caption>
<p>The relative protein expression of three cell lines. <sup>*</sup>p&lt;0.001; <sup>**</sup>p&lt;0.001; <sup>***</sup>p=0.081.</p></caption>
<graphic xlink:href="OR-32-03-1108-g11.gif"/></fig>
<fig id="f13-or-32-03-1108" position="float">
<label>Figure 13</label>
<caption>
<p>Apoptosis rate of three cell lines. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells. <sup>*</sup>p=0.019; <sup>**</sup>p=0.016; <sup>***</sup>p=0.890.</p></caption>
<graphic xlink:href="OR-32-03-1108-g12.gif"/></fig>
<fig id="f14-or-32-03-1108" position="float">
<label>Figure 14</label>
<caption>
<p>CCK-8 detection of the effect of DJ-1 gene on the proliferation of SNU-46. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells. <sup>*</sup>p&lt;0.001; **p&lt;0.001.</p></caption>
<graphic xlink:href="OR-32-03-1108-g13.gif"/></fig>
<fig id="f15-or-32-03-1108" position="float">
<label>Figure 15</label>
<caption>
<p>Transwell assay detection of DJ-1 gene impact on the invasion of SNU-46. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells. <sup>*</sup>p=0.001; <sup>**</sup>p=0.001; <sup>***</sup>p=0.794.</p></caption>
<graphic xlink:href="OR-32-03-1108-g14.gif"/></fig>
<fig id="f16-or-32-03-1108" position="float">
<label>Figure 16</label>
<caption>
<p>Transwell assay detection of DJ-1 gene impact on migration of SNU-46. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells. <sup>*</sup>p=0.036; <sup>**</sup>p=0.027; <sup>***</sup>p=0.850.</p></caption>
<graphic xlink:href="OR-32-03-1108-g15.gif"/></fig>
<fig id="f17-or-32-03-1108" position="float">
<label>Figure 17</label>
<caption>
<p>Western blot detection of SNU-46-D1 cells. p-AKT, AKT protein expression levels. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g16.gif"/></fig>
<fig id="f18-or-32-03-1108" position="float">
<label>Figure 18</label>
<caption>
<p>Western blot detection of p-mTOR, mTOR protein levels in SNU-46-D1 cells. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g17.gif"/></fig>
<fig id="f19-or-32-03-1108" position="float">
<label>Figure 19</label>
<caption>
<p>Western blot detection of SNU-46-D1 cells. PTEN protein expression level. N, SNU-46 cells; C, SNU-46-CON cells; D1, SNU-46-D1 cells.</p></caption>
<graphic xlink:href="OR-32-03-1108-g18.gif"/></fig></floats-group></article>
